Bio-Rad Laboratories anti-idiotypic antibodies

Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies. These ready-made antibodies are suitable for developing selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for dupilumab, evolocumab, ipilimumab and secukinumab, and their biosimilars.

Dupilumab limits inflammatory immune responses by targeting IL-4Ra and is approved for treatment of severe atopic eczema. Bio-Rad’s six new anti-dupilumab antibodies can be used to develop PK bridging ELISAs to measure free and total drug, or as a surrogate positive control or reference standard in ADA assays. The range includes two fully human IgG1 clones and four TrailBlazer Antibodies with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast switching to a bivalent Fab or a full-length Ig-like format within an hour.

The company has also expanded its anti-ipilimumab and anti-secukinumab portfolio to provide antibodies specific to the drug-target complex, allowing the detection of bound drugs. HRP-labelled TrailBlazer antibodies are also now available for evolocumab.

The anti-idiotypic antibodies are approved for in vitro research, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring. They are provided with in-depth data packages for reproducible results.